Predictive Value of BRAF^V600E Mutation for Lymph Node Metastasis in Papillary Thyroid Cancer: A Meta-analysis

Abstract

BRAF^V600E mutation has been thought to be a valuable molecular marker that may predict a worse prognosis for papillary thyroid cancer (PTC). But whether BRAF^V600E mutation is associated with lymph node metastasis (LNM) remains controversial. Different surgical strategies may bring a bias in demonsstrating the association between them. In order to delineate a risk stratification to guide a tailored initial approach to tumors that express BRAF^V600E mutation, we performed this meta-analysis by using the articles in which total or near-total thyroidectomy plus bilateral central lymph node dissection was routinely performed to avoid the bias from the surgical strategy. We searched the Medline, Embase and CNKI database for eligible studies from January 2003 to May 2018. Meta-analysis was performed using the STATA 12.0 software. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated under fixed-effects or randomeffects models. Fifteen clinical studies were included with a total of 4909 PTC patients. Our meta-analysis results reported that BRAFV600E mutation was associated with LNM (OR=1.34; 95% CI: 1.09–1.65; P=0.005), as well as central LNM (OR=1.59; 95% CI: 1.35–1.88; P<0.00001). Moreover, in patients with papillary thyroid microcarcinoma, we also confirmed the predictive value of BRAF^V600E mutation for LNM (OR=3.49; 95% CI: 2.02–6.02; P<0.00001). This meta-analysis demonstrates that BRAF^V600E mutation is closely related to LNM in PTC patients. The results suggest that BRAF^V600E mutation can be considered as a risk factor for LNM in PTC. Moreover, combining BRAF^V600E mutation with other risk factors to determine the initial surgical treatment may bring benefits for PTC patients.

Keywords

B-Raf proto-oncogene / thyroid cancer / papillary thyroid carcinoma / lymph node metastasis / meta-analysis

References

[1] PellegritiG, FrascaF, RegalbutoC, et al.. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol, 2013, 2013: 965212

[2] DaviesL, WelchHG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA, 2006, 295(18): 2164-2167

[3] HundahlSA, FlemingID, FremgenAM, et al.. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U. S., 1985–1995 [see commetns]. Cancer, 1998, 83(12): 2638-2648

[4] LohKC, GreenspanFS, GeeL, et al.. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab, 1997, 82(11): 3553-3562

[5] HundahlSA, CadyB, CunninghamMP, et al.. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U. S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer, 2000, 89(1): 202-217

[6] ShermanSI, AngelosP, BallDW, et al.. Thyroid carcinoma. J Natl Compr Canc Netw, 2005, 3(3): 404-457

[7] MazzaferriEL, JhiangSM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med, 1994, 97(5): 418-428

[8] NikiforovaMN, KimuraET, GandhiM, et al.. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab, 2003, 88(11): 5399-5404

[9] KimKH, KangDW, KimSH, et al.. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J, 2004, 45(5): 818-821

[10] XingM, WestraWH, TufanoRP, et al.. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab, 2005, 90(12): 6373-6379

[11] KimJ, GiulianoAE, TurnerRR, et al.. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg, 2006, 244(5): 799-804

[12] NakayamaH, YoshidaA, NakamuraY, et al.. Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. Anticancer Res, 2007, 27(5B): 3645-3649

[13] KebebewE, WengJ, BauerJ, et al.. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg, 2007, 246(3): 466-470

[14] LupiC, GianniniR, UgoliniC, et al.. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab, 2007, 92(11): 4085-4090

[15] RodolicoV, CabibiD, PizzolantiG, et al.. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases. Cancer, 2007, 110(6): 1218-1226

[16] FrascaF, NuceraC, PellegritiG, et al.. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer, 2008, 15(1): 191-205

[17] GuanH, JiM, BaoR, et al.. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab, 2009, 94(5): 1612-1617

[18] LeeX, GaoM, JiY, et al.. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol, 2009, 16(2): 240-245

[19] OlerG, CeruttiJM. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer, 2009, 115(5): 972-980

[20] GongRX, ZhouY, LuoSH, et al.. An investigation of BRAF mutation in papillary thyroid carcinoma and its clinical value. Zhonghua Yi Xue Yi Chuan Xue Za Zhi (Chinese), 2009, 26(3): 310-313

[21] BasoloF, TorregrossaL, GianniniR, et al.. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab, 2010, 95(9): 4197-4205

[22] SykorovaV, DvorakovaS, RyskaA, et al.. BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic. J Endocrinol Invest, 2010, 33(5): 318-324

[23] SoYK, SonYI, ParkJY, et al.. Preoperative BRAF mutation has different predictive values for lymph node metastasis according to tumor size. Otolaryngol Head Neck Surg, 2011, 145(3): 422-427

[24] JunfengLU, XieN, YinanJI. The Correlation between BRAFV600E Gene Mutation and p27 Expression and Lymph Node Metastasis of Papillary Thyroid Carcinoma. Hebei Yixue (Chinese), 2011, 17: 711-714

[25] LeeJI, JangHW, KimSW, et al.. BRAFV600E mutation in fine-needle aspiration aspirates: Association with poorer prognostic factors in larger papillary thyroid carcinomas. Head Neck, 2013, 35(4): 548-553

[26] GaoWL, WieLL, ChaoYG, et al.. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas. Clin Lab, 2012, 58(9–10): 919-926

[27] ChakrabortyA, NarkarA, MukhopadhyayaR, et al.. BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion. Endocr Pathol, 2012, 23(2): 83-93

[28] GuerraA, FugazzolaL, MarottaV, et al.. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin Endocrinol Metab, 2012, 97(7): 2333-2340

[29] JooJY, ParkJY, YoonYH, et al.. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study. J Clin Endocrinol Metab, 2012, 97(11): 3996-4003

[30] KimSJ, LeeKE, MyongJP, et al.. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg, 2012, 36(2): 310-317

[31] KurtulmusN, DurenM, InceU, et al.. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Endocrine, 2012, 42(2): 404-410

[32] ZhengX, XiaT, LinL, et al.. BRAFV600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China. World J Surg Oncol, 2012, 10: 104

[33] ZhaoHT, ZhaoCQ, ZhangB. Expression and significance of CD44v6, BRAF and Rasp21 in papillary thyroid carcinoma. Zhongguo Zhongliu Linchuang Yu Kangfu (Chinese), 2012, 19(4): 310-312

[34] YiW, ZhongD, ZouQ. BRAF mutation and papillary thyroid cancer. Zhong Nan Da Xue Xue Bao Yi Xue Ban (Chinese), 2012, 37(4): 370-373

[35] AlzahraniAS, XingM. Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND. Endocr Relat Cancer, 2013, 20(1): 13-22

[36] GouveiaC, CanNT, BostromA, et al.. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience. JAMA Otolaryngol Head Neck Surg, 2013, 139(11): 1164-1170

[37] HowellGM, NikiforovaMN, CartySE, et al.. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol, 2013, 20(1): 47-52

[38] JeongD, JeongY, ParkJH, et al.. BRAF (V600E) mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR. Ann Surg Oncol, 2013, 20(3): 759-766

[39] LiC A, HanP, LeeKC, et al.. Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers. J Clin Endocrinol Metab, 2013, 98(9): 3702-3712

[40] RossiED, MartiniM, CapodimontiS, et al.. BRAF (V600E) mutation analysis on liquid-based cytologyprocessed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma. Cancer Cytopathol, 2013, 121(6): 291-297

[41] ZhengX, WeiS, HanY, et al.. Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases. Ann Surg Oncol, 2013, 20(7): 2266-2273

[42] LimJY, HongSW, LeeYS, et al.. Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center. Thyroid, 2013, 23(11): 1423-1430

[43] PuYB. Clinical significance of BRAFV600E in papillary thyroid cancer. Shiyong Aizheng Zazhi (Chinese), 2013, 28(3): 246-248

[44] JiangX, XieN. Expression and significance of the BRAFV600E-mutated Protein in papillary thyroid carcinoma. Guangdong Yixue (Chinese), 2013, 34: 931-933

[45] YipL, NikiforovaMN, YooJY, et al.. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients. Ann Surg, 2015, 262(3): 519-525

[46] BastosAU, OlerG, NozimaBH, et al.. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma. Eur J Endocrinol, 2015, 173(4): 525-540

[47] KimSK, WooJW, LeeJH, et al.. Role of BRAFV600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma. Surgery, 2015, 158(6): 1500-1511

[48] ShiCL, SunY, DingC, et al.. Correlation between the BRAFV600E mutation status and the clinicopathologic features of papillary thyroid carcinoma. Genet Mol Res, 2015, 14(3): 7377-7385

[49] FraserS, GoC, AnissA, et al.. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer. World J Surg, 2016, 40(7): 1618-1624

[50] QuHJ, QuXY, HuZ, et al.. The synergic effect of BRAF(V600E) mutation and multifocality on central lymph node metastasis in unilateral papillary thyroid carcinoma. Endocr J, 2018, 65(1): 113-120

[51] NambaH, NakashimaM, HayashiT, et al.. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab, 2003, 88(9): 4393-4397

[52] YinXL, ZhangGC, FengLI, et al.. BRAFV600E Mutation in Papillary Thyroid Cancer by MASAPCR. Shihezi Daxue Xuebao (Ziran Kexue Ban), 2005, 23: 552-554

[53] ZhuXL, ZhouXY, ZhuXZ. BRAFV599E mutation and RET/PTC rearrangements in papillary thyroid carcinoma. Zhonghua Bing Li Xue Za Zhi (Chinese), 2005, 34(5): 270-274

[54] KimTY, KimWB, SongJY, et al.. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf), 2005, 63(5): 588-593

[55] LiuRT, ChenYJ, ChouFF, et al.. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf), 2005, 63(4): 461-466

[56] AdeniranAJ, ZhuZ, GandhiM, et al.. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol, 2006, 30(2): 216-222

[57] FugazzolaL, PuxedduE, AveniaN, et al.. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer, 2006, 13(2): 455-464

[58] JoYS, LiS, SongJH, et al.. Influence of the BRAFV600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab, 2006, 91(9): 3667-3670

[59] KimTY, KimWB, RheeYS, et al.. The BRAF mutation is useful for prediction of clinical recurrence in lowrisk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf), 2006, 65(3): 364-368

[60] LeeJH, LeeES, KimYS, et al.. BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas. Pathology, 2006, 38(3): 201-204

[61] AbrosimovA, SaenkoV, RogounovitchT, et al.. Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status. Int J Cancer, 2007, 120(1): 196-200

[62] CostaAM, HerreroA, FresnoMF, et al.. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf, 2008, 68(4): 618-634

[63] EliseiR, UgoliniC, ViolaD, et al.. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab, 2008, 93(10): 3943-3949

[64] NiuW, LuoYQ, ChenLR. Clinical significance of BRAF mutation and expression in papillary thyroid carcinoma. Journal of Practical Oncology, 2008, 23(6): 519-523

[65] MiZ, WangA, ZhaoZ, et al.. Study of BRAFV600E mutation in papillary thyroid cancer. Shaanxi Med J (Chinese), 2008, 37: 1471-1477

[66] ItoY, YoshidaH, MaruoR, et al.. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J, 2009, 56(1): 89-97

[67] KwakJY, KimEK, ChungWY, et al.. Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology, 2009, 253(3): 854-860

[68] ZangX, ChenJ, LinH, et al.. The research of BRAFV600E mutation in papillary thyroid cancer. Xiandai Shiyong Yixue (Chinese), 2009, 21: 1296

[69] LinKL, WangOC, ZhangXH, et al.. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol, 2010, 17(12): 3294-3300

[70] StanojevicB, DzodicR, SaenkoV, et al.. Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia. Endocr J, 2011, 58(5): 381-393

[71] EloyC, SantosJ, SoaresP, et al.. The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Arch, 2011, 459(3): 265-276

[72] PelizzoMR, BoschinIM, BarolloS, et al.. BRAF analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience. Clin Chem Lab Med, 2011, 49(2): 325-329

[73] ZhengX, XiaT, LinL, et al.. BRAFV600E Mutational Status and Ciinico-biological Characteristics of Multifocal Papillary Thyroid Carcinomas. Zhongguo Zhongliu Linchuang (Chinese), 2011, 38: 1326-1329

[74] DaiY, LiB, WangS. The association between BRAF mutation and lymph node metastasis in papillary thyroid cancer. Zhongguo Yixue Chuangxin (Chinese), 2011, 8(31): 29-30

[75] PaulsonL, ShindoM, SchuffK, et al.. The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg, 2012, 138(1): 44-49

[76] KoperekO, KornauthC, CapperD, et al.. Immunohistochemical detection of the BRAF V600Emutated protein in papillary thyroid carcinoma. Am J Surg Pathol, 2012, 36(6): 844-850

[77] AhnD, ParkJS, SohnJH, et al.. BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma. Auris Nasus Larynx, 2012, 39(2): 198-203

[78] KurtB, YalcinS, AlagozE, et al.. The relationship of the BRAF(V600E) mutation and the established prognostic factors in papillary thyroid carcinomas. Endocr Pathol, 2012, 23(3): 135-140

[79] LeeKC, LiC, SchneiderEB, et al.. Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer. Surgery, 2012, 152(6): 977-983

[80] LeeST, KimSW, KiCS, et al.. Clinical implication of highly sensitive detection of the BRAFV600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area. J Clin Endocrinol Metab, 2012, 97(7): 2299-2306

[81] NamJK, JungCK, SongBJ, et al.. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer. Am J Surg, 2012, 203(4): 436-441

[82] SassolasG, Hafdi-NejjariZ, FerraroA, et al.. Oncogenic alterations in papillary thyroid cancers of young patients. Thyroid, 2012, 22(1): 17-26

[83] UlisseS, BaldiniE, SorrentiS, et al.. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with diseasefree interval. Clin Endocrinol (Oxf), 2012, 77(5): 780-786

[84] Xiao-QiangLI, ZhangHZ, JiangZM, et al.. Expression of BRAF gene and its significance in papillary thyroid carcinoma. J Clin Exp Pathol, 2012, 28: 991-995

[85] XiaT, ChuanxiangHU, ZhaoJ, et al.. BRAFV600E Mutation in Papillary Thyroid Carcinoma. Chin J Clin Oncol (Chinese), 2012, 7(2): 439-443

[86] KimYS, KimJS, BaeJS, et al.. Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma. World J Surg Oncol, 2013, 11: 99

[87] FernandezIJ, PiccinO, SciasciaS, et al.. Clinical significance of BRAF mutation in thyroid papillary cancer. Otolaryngol Head Neck Surg, 2013, 148(6): 919-925

[88] GandolfiG, SancisiV, TorricelliF, et al.. Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression. J Clin Endocrinol Metab, 2013, 98(5): E934-E942

[89] McKelviePA, ChanF, YuY, et al.. The prognostic significance of the BRAF V600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry. Pathology, 2013, 45(7): 637-644

[90] ChoiSY, ParkH, KangMK, et al.. The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors. World J Surg Oncol, 2013, 11: 291

[91] ZagzagJ, PollackA, DultzL, et al.. Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma. Surgery, 2013, 154(6): 1199-1204

[92] GongY, GongR, YangJ, et al.. The association between BRAF mutation and clinicopathological characteristics and its clinical implication in papillary thyroid cancer. Sichuan Da Xue Xue Bao Yi Xue Ban (Chinese), 2013, 44: 662-665

[93] ZhengL, HuX. Significance of expressions of HBME-1, Galectin-3, CK19 and BRAF mutation in papillary thyroid carcinoma. Anhui Yike Daxue Xuebao (Chinese), 2013, 48(4): 401-405

[94] DanilovicDL, LimaEU, DominguesRB, et al.. Preoperative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma. Eur J Endocrinol, 2014, 170(4): 619-625

[95] WalczykA, KowalskaA, KowalikA, et al.. The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome. Clin Endocrinol (Oxf), 2014, 80(6): 899-904

[96] WaltsAE, MirochaJM, BoseS. Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status. J Cancer Res Clin Oncol, 2015, 141(10): 1749-1756

[97] ParkVY, KimEK, LeeHS, et al.. Real-Time PCR Cycle Threshold Values for the BRAFV600E Mutation in Papillary Thyroid Microcarcinoma May Be Associated With Central Lymph Node Metastasis: A Retrospective Study. Medicine (Baltimore), 2015, 94(28): e1149

[98] CzarnieckaA, KowalM, RusinekD, et al.. The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors. PLoS One, 2015, 10(7): e0132821

[99] LinJD, FuSS, ChenJY, et al.. Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene. Thyroid, 2016, 26(5): 691-704

[100] SunJ, ZhangJ, LuJ, et al.. BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients. PLoS One, 2016, 11(4): e0153319

[101] ParkVY, KimEK, MoonHJ, et al.. The thyroid imaging reporting and data system on US, but not the BRAFV600E mutation in fine-needle aspirates, is associated with lateral lymph node metastasis in PTC. Medicine (Baltimore), 2016, 95(29): e4292

[102] FakhruddinN, JabbourM, NovyM, et al.. BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases. Sci Rep, 2017, 7(1): 4666

[103] TufanoRP, TeixeiraGV, BishopJ, et al.. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore), 2012, 91(5): 274-286

[104] KimTH, ParkYJ, LimJA, et al.. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer, 2012, 118(7): 1764-1773

[105] ZhangQ, LiuSZ, ZhangQ, et al.. Meta-Analyses of Association Between BRAF(V600E) Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma. Cell Physiol Biochem, 2016, 38(2): 763-776

[106] MaB, WangY, YangS, et al.. Predictive factors for central lymph node metastasis in patients with cN0 papillary thyroid carcinoma: A systematic review and meta-analysis. Int J Surg, 2016, 28: 153-161

[107] LiuC, ChenT, LiuZ. Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a metaanalysis. World J Surg Oncol, 2016, 14(1): 241

[108] LeeJH, LeeES, KimYS. Clinicopathologic significance of BRAFV600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer, 2007, 110(1): 38-46

[109] ZimmermannAK, CamenischU, RechsteinerMP, et al.. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma. Cancer Cytopathol, 2014, 122(1): 48-58

[110] FisherKE, NeillSG, EhsaniL, et al.. Immunohistochemical investigation of BRAF p. V600E mutations in thyroid carcinoma using 2 separate BRAF antibodies. Appl Immunohistochem Mol Morphol, 2014, 22(8): 562-567

[111] StulakJM, GrantCS, FarleyDR, et al.. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg, 2006, 141(5): 489-494

[112] VergezS, SariniJ, PercodaniJ, et al.. Lymph node management in clinically node-negative patients with papillary thyroid carcinoma. Eur J Surg Oncol, 2010, 36(8): 777-782

[113] ConzoG, PasqualiD, BellastellaG, et al.. Total thyroidectomy, without prophylactic central lymph node dissection, in the treatment of differentiated thyroid cancer. Clinical retrospective study on 221 cases. Endocrine, 2013, 44(2): 419-425

[114] BarczynskiM, KonturekA, StopaM, et al.. Prophylactic central neck dissection for papillary thyroid cancer. Br J Surg, 2013, 100(3): 410-418

[115] ChisholmEJ, KulinskayaE, TolleyNS. Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscope, 2009, 119(6): 1135-1139

[116] GloverAR, GundaraJS, NorlenO, et al.. The pros and cons of prophylactic central neck dissection in papillary thyroid carcinoma. Gland Surg, 2013, 2(4): 196-205

[117] RosenbaumMA, McHenryCR. Central neck dissection for papillary thyroid cancer. Arch Otolaryngol Head Neck Surg, 2009, 135(11): 1092-1097

[118] YuXM, WanY, SippelRS, et al.. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg, 2011, 254(4): 653-660

[119] WardLS, MorariEC, LeiteJL, et al.. Identifying a risk profile for thyroid cancer. Arq Bras Endocrinol Metabol, 2007, 51(5): 713-722

[120] ZhouYL, ZhangW, GaoEL, et al.. Preoperative BRAF mutation is predictive of occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma. Asian Pac J Cancer Prev, 2012, 13(4): 1267-1272